




RealRate

PHARMACEUTICAL 2019

Cumberland Pharmaceuticals INC
Rank 187 of 361



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Cumberland Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Cumberland Pharmaceuticals INC compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 47% points. The greatest weakness of Cumberland Pharmaceuticals INC is the variable Liabilities, reducing the Economic Capital Ratio by 38% points.

The company's Economic Capital Ratio, given in the ranking table, is 256%, being 6.9% points above the market average of 250%.

Input Variable	Value in 1000 USD
Assets, Current	59,116
Cost of Goods Sold	7,378
Intangible Assets	34,439
Liabilities, Current	27,804
Liabilities, Non-Current	9,319
Other Assets	18,368
Other Compr. Net Income	0
Other Expenses	23,240
Other Liabilities	20,000
Other Net Income	564
Other Revenues	40,742
Property and Equipment	771
Research and Development	7,321
Selling, General and Administrative Expense	10,406

Output Variable	Value in 1000 USD
Assets	112,694
Liabilities	57,123
Expenses	48,345
Revenues	40,742
Stockholders Equity	55,571
Net Income	-7,039
Comprehensive Net Income	-7,039
BaseVar	129,734
ECR before Limited Liability	134%
Economic Capital Ratio	256%